Pfizer prospects for tafamidis market

Pfizer expects the Food and Drug Administration to decide in July on approval of tafamidis in the rare disease transthyretin amyloid cardiomyopathy. Assuming the regulator gives an OK, the big pharma company will need to overcome underdiagnosis, as the condition is often mistaken for heart failure, as well as payer resistance to what is likely to be a costly drug.